Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4233)	1/14/2003 4:04:52 PM
From: pz	Read Replies (1) \| Respond to of 5582

Dan, Well I found out why Zicam didn't take care of my "cold." It turns out that it wasn't a cold at all, but allergies (likely cedar), from your part of the state. I took some Claritin and it flat took care of it. If you suffer from cedar, you might give Claritin a try. Paul

To: DanZ who wrote (4233)	2/4/2003 2:19:42 PM
From: Mike M	Read Replies (1) \| Respond to of 5582

Zicam continues to sell very well. File under "nosing" ahead of the competition. biz.yahoo.com <<Zicam Products Dominate 2002 Nasal Product Sales Tuesday February 4, 8:02 am ET Matrixx Initiatives' Zicam(R) Brand Cold Products Are Five of Top 10 Sellers in Q4 PHOENIX, Feb. 4 /PRNewswire-FirstCall/ -- Zicam® cold and allergy remedies are beating the competition -- cold. Recent syndicated research drug sales data show sales of Zicam Cold Remedy nasal gel, Zicam Allergy Relief, Zicam Cold Remedy Swabs, Zicam Kids Size Cold Remedy Swabs, and Zicam Extreme Congestion Relief nosing ahead of competitive products. Manufactured by Matrixx Initiatives, Inc. (Nasdaq: MTXX - News), the products represented five of the top 10 items (SKUs) on a dollar sales per point of distribution basis among cold and allergy internal nasal products sold in drug stores during the last 12 weeks of 2002. "The response from consumers this cold season has been amazing," said Carl J. Johnson, president and chief executive officer of Matrixx. "The cold and allergy categories are highly competitive. To accomplish these results against the larger brands reflects a tremendous acceptance from consumers and support from innovative retailers for the unique Zicam formulas." The impressive sales performance underscores Matrixx's continued growth, and the success of the company's new product development strategy, which in 2002 focused on expanding the successful Zicam line of gel-based nasal products with the launch of five new items. The company currently markets seven SKUs of Zicam products, which are widely available at food, drug and mass merchandise stores throughout the U.S.>>

To: DanZ who wrote (4233)	2/25/2003 12:44:06 PM
From: pz	Read Replies (1) \| Respond to of 5582

Dan, This can't be good................ Paul The Quigley Corporation Introduces COLD-EEZE Nasal Spray Tuesday February 25, 7:31 am ET Contains Zinc Gluconate To Treat Common Cold and Aloe Vera to Soothe Nasal Passages DOYLESTOWN, Pa.--(BUSINESS WIRE)--Feb. 25, 2003--The Quigley Corporation (Nasdaq:QGLY - News) originator of the zinc cold product category, announced today the launch of a new offering in its COLD-EEZE line of remedies. ADVERTISEMENT The product, a moisturizing nasal spray containing the active ingredient Zinc Gluconate and also containing Aloe Vera gel, will begin shipping to retail in July. The new COLD-EEZE Nasal Spray is designed to effectively reduce the duration of symptoms of the common cold. Its 0.68 mg of Zinc Gluconate per dose penetrates nasal, sinus and throat cavities to deliver the zinc ions where they are needed most. Additionally, the spray contains Aloe Vera gel to help soothe nasal passages that are dry and inflamed. The formula is non-habit forming and will not interact with other medicines. "The COLD-EEZE Nasal Spray, manufactured under U.S. patent # 5,622,724, leverages our strong equity in cold care and broadens our portfolio of zinc cold remedies," said Guy Quigley, president and CEO of the Quigley Corporation. "Along with the proven efficacy of our lozenges and gum, the new Nasal Spray complements our existing COLD-EEZE line while offering consumers a new alternative in their fight to get better faster." The COLD-EEZE Nasal Spray will be sold in a dynamic package that allows consumers to recognize the product as part of the COLD-EEZE line. The launch of the Nasal Spray will be supported with an integrated marketing campaign, including advertising, public relations and in-store support. Study Shows: Treat it with the COLD-EEZE Lozenges In a retrospective study conducted over three years at the Heritage School facility in Provo, Utah, 378 adolescents ranging in age from 12 to 18 were given COLD-EEZE both prophylactically and symptomatically for more than 170,000 patient days. The study found that COLD-EEZE, when taken daily, statistically lessened the number of colds study participants suffered per year by over 50%. The colds that did develop lasted for an average period of 6 days when treated with COLD-EEZE and 10 days when not. The study also found that the use of COLD-EEZE to treat a cold statistically reduced antibiotic use for respiratory illnesses by 92%. In a double-blind, placebo-controlled study conducted at the Cleveland Clinic and published in the Annals of Internal Medicine, those patients taking COLD-EEZE recovered completely from their colds more than three days faster (on average) than the patients who received a placebo. In addition, individual symptoms went away faster. On average, the COLD-EEZE group had 2.5 fewer days of coughing, 1 less day of headache, 1 less day of hoarseness, 2 fewer days of nasal congestion, 3 fewer days of nasal drainage and 2 fewer days of sore throat.